Not logged in Share Save
Share Save
Share Save
Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial Gordon, A.; Rajan, Z.; Fong, C. Y. K.; Peckitt, C.; Satchwell, L.; Cromarty, S.; Kidd, S.; Piadel, K.; Leamon, B.; Zhitkov, O.; Davidson, M.; Thompson, J.; Maisey, N. R.; Darby, S.; Waddell, T. S.; Morgan, C.; Bradshaw, A.; Starling, N.; Chau, I.; Cunningham, D. Share Save
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients Lote, Hazel; Mousoullou, Florentia; Vlachogiannis, George; Lampis, Andrea; Satchwell, Laura; Peckitt, Clare; Fong, Caroline; Begum, Ruwaida; Kidd, Shannon; Cromarty, Susan; Gordon, Anderley; Fribbens, Charlotte; Rao, Sheela; Starling, Naureen; Chau, Ian; Cunningham, David; Valeri, Nicola Share Save
Maintenance rucaparib after first-line platinum-based chemotherapy in advanced esophagogastric (OG) adenocarcinoma: Interim results from the PLATFORM trial Gordon, A.; Fong, C. Y. K.; Davidson, M.; Cromarty, S.; Kidd, S.; Piadel, K.; Peckitt, C.; Satchwell, L.; Rajan, Z.; Begum, R.; Zhitkov, O.; Das, P.; Sothi, S.; Herbertson, R. A.; Darby, S.; Waddell, T. S.; Bradshaw, A.; Starling, N.; Chau, I.; Cunningham, D. Share Save
Circulating tumor DNA for recurrence prediction and efficacy analysis in the ICONIC trial of peri-operative FLOT and avelumab (PD-L1) in localized esophago-gastric adenocarcinoma Gerlinger, Marco; Gordon, Anderley; Barber, Louise J.; Laliotis, Georgios; Athauda, Avani; Challoner, Benjamin; Woolston, Andrew; Mansukhani, Sonia; Dunstan, Matt; Petrou, Nikoletta; Khabra, Komel; Lazaro-Alcausi, Retchel; Crux, Richard; Borja, Victoria; Begum, Ruwaida; Rana, Isma; Palsuledesai, Charuta; Malhotra, Meenakshi; Liu, Minetta; Jurdi, Adham; Sharma, Shruti; Rao, Sheela; Kumar, Sacheen; Cunningham, David; Chau, Ian; Starling, Naureen; Chaudry, M. Asif Share Save
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib Guinn, D.; Ruppert, A. S.; Maddocks, K.; Jaglowski, S.; Gordon, A.; Lin, T. S.; Larson, R.; Marcucci, G.; Hertlein, E.; Woyach, J.; Johnson, A. J.; Byrd, J. C. Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
